SVRA
HealthcareSavara Inc. · Biotechnology · $1B
What is Savara Inc.?
Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases. Based in Austin, Texas, the company is advancing a single lead asset through late-stage clinical trials.
Savara's business centers on researching and developing inhaled therapies for rare lung conditions. Its lead program targets autoimmune pulmonary alveolar proteinosis, a rare disease in which abnormal protein buildup impairs lung function. The company earns no product revenue at this stage — its value proposition rests entirely on the clinical and regulatory success of its pipeline. Savara operates as a pre-commercial entity, funding operations through capital markets.
Savara was founded in 2017 and is headquartered in Austin, Texas.
- Molgramostim — inhaled GM-CSF therapy in Phase III development
- Autoimmune pulmonary alveolar proteinosis treatment program
- Rare respiratory disease pipeline focus
Is SVRA a Good Stock to Buy?
UQS Score rates SVRA as Poor overall, reflecting the early-stage nature and financial profile typical of pre-revenue clinical biotechs.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet or near-term financial exposure is managed better than peers at a similar development stage. Valuation is rated Elevated, which is notable context for investors weighing entry points.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial products, no recurring revenue, and a pipeline dependent on a single late-stage asset.
Pro members can view the complete pillar breakdown and underlying financial metrics to form a fuller picture of SVRA's risk-reward profile. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SVRA pay dividends?
No — Savara Inc. does not currently pay a dividend.
Savara does not pay a dividend, which is standard for clinical-stage biopharmaceutical companies. All available capital is directed toward funding clinical trials and advancing molgramostim through regulatory review. Income-focused investors should not expect distributions from SVRA in the near term.
When does SVRA report earnings?
Savara Inc. reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Pipeline milestones and enrollment updates tend to drive more market attention than the income statement.
For the most recent quarter's results and management commentary, visit Savara's investor relations page directly.
SVRA Price History
+193.3% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Savara Inc.?
Based on Savara Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SVRA Long-term Outlook
Savara's fundamental outlook is shaped almost entirely by the trajectory of its Phase III molgramostim program. The Growth pillar is rated Weak, reflecting the absence of commercial revenue and the binary nature of clinical-stage development. The Risk pillar rating of Good provides some reassurance around near-term financial stability, but the path to value creation runs through regulatory outcomes rather than organic business expansion.
Growth drivers
- Potential Phase III readout for molgramostim in autoimmune PAP
- Rare disease designation pathways that may accelerate regulatory review
- Unmet medical need in a condition with limited approved therapies
Key risks
- Clinical trial failure or unfavorable data readout for the lead asset
- Elevated valuation relative to current development stage and lack of revenue
- Ongoing capital needs typical of pre-commercial biopharmaceutical companies
SVRA vs Peers
Savara operates in a competitive rare-disease and clinical-stage biopharma landscape alongside several other development-stage companies.
Septerna focuses on G protein-coupled receptor drug discovery, pursuing a broader target class than Savara's single inhaled respiratory asset.
Precigen applies synthetic biology and gene engineering platforms across oncology and other disease areas, contrasting with Savara's narrow respiratory focus.
Biohaven pursues a diversified neurological and rare-disease pipeline, giving it broader therapeutic exposure compared to Savara's single-program model.
Frequently Asked Questions
What does Savara Inc. do?
Savara is a clinical-stage biopharmaceutical company developing inhaled therapies for rare respiratory diseases. Its lead candidate, molgramostim, is in Phase III trials for autoimmune pulmonary alveolar proteinosis — a rare condition where abnormal protein accumulation impairs breathing. The company has no approved products or commercial revenue at this time.
Does SVRA pay dividends?
No, Savara does not pay a dividend. Pre-revenue clinical-stage companies typically reinvest all capital into research and development. Investors in SVRA are betting on pipeline success rather than income distributions.
When does SVRA report earnings?
Savara reports on a standard quarterly schedule. Because the company has no product revenue, reports center on operating expenses and cash position. Check Savara's investor relations page for the latest filing dates and earnings call details.
Is SVRA a good stock to buy?
UQS Score rates SVRA as Poor overall. Quality, Moat, and Growth pillars are all Weak, reflecting the pre-commercial stage. Risk scores relatively better, but Valuation is Elevated. Whether the risk-reward is appropriate depends on an investor's conviction in the clinical program and tolerance for binary outcomes.
Is SVRA overvalued?
The UQS Valuation pillar for SVRA is rated Elevated, suggesting the market may be pricing in optimistic clinical outcomes. For a company with no revenue, valuation is inherently speculative and tied to pipeline probability. Pro members can see the detailed valuation metrics behind this rating.
How does SVRA compare to its competitors?
Savara is narrower in focus than peers like Biohaven or Precigen, which pursue diversified pipelines across multiple disease areas. That concentration can amplify both upside and downside. UQS Score provides side-by-side pillar comparisons for SVRA and its peers for Pro members.
What is SVRA's market cap bracket?
Savara is classified as a small-cap company. This places it in a segment of the market that typically carries higher volatility and liquidity risk compared to large- or mega-cap peers, which is common for clinical-stage biotechs.
Who founded Savara Inc.?
Savara was founded in 2017. Details on the founding team are publicly available through the company's official filings and investor relations materials on its website.
Is SVRA a long-term quality investment?
From a quality indicator standpoint, SVRA's UQS profile — with Weak scores across Quality, Moat, and Growth — reflects the structural limitations of a single-asset clinical company. Long-term quality typically requires durable revenue, competitive advantages, and consistent growth, none of which Savara has established yet.
What is the main competitive advantage of Savara Inc.?
Savara's potential advantage lies in targeting a rare disease with limited treatment options, which may support orphan drug designations and a less crowded competitive field. However, the UQS Moat pillar is rated Weak, indicating that durable competitive advantages have not yet been established at this stage.
What sector does SVRA belong to?
Savara operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on rare respiratory diseases, a niche that can attract regulatory incentives but also carries concentrated pipeline risk.
Is SVRA a growth stock or value stock?
Based on UQS pillar labels, SVRA does not fit neatly into either category. Growth is rated Weak due to the absence of revenue, while Valuation is Elevated — meaning investors are paying a premium without current financial performance to support it. It is best characterized as a speculative clinical-stage bet.
Unlock Full SVRA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics behind each pillar
- ✓Compare SVRA side-by-side with clinical-stage peers
- ✓Track pillar changes as new data becomes available
- ✓Screen rare-disease biotechs by Risk and Valuation labels
Pro Analysis
SVRA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 15, 2026 | 14.2 | 0.0 | 11.0 | 1.3 | 74.6 | 0.0 | -0.1 |
| Apr 22, 2026 | 14.3 | 0.0 | 11.0 | 1.3 | 75.0 | 0.0 | 0.0 |
| Apr 2, 2026 | 14.3 | 0.0 | 11.0 | 1.7 | 75.0 | 0.0 | — |
SVRA — Pillar Breakdown
Quality
— 0.0/100 (25%)Savara Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 1.3/100 (20%)Savara Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 74.6/100 (15%)Savara Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Savara Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Savara Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SVRA.
Score Composition
Financial Data
More Stock Analysis
How is the SVRA UQS Score Calculated?
The UQS (Unified Quality Score) for Savara Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Savara Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Savara Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.